Recent studies have unveiled promising links between the use of GLP-1 medications and a decreased risk of certain cancers. This revelation comes at a time when semaglutide, a prominent GLP-1 drug, is becoming increasingly accessible in Canada, with generic versions anticipated to hit pharmacies this year. The findings were discussed in detail at the recent American Society of Clinical Oncology meeting in Chicago, where the research indicated that patients on GLP-1 treatments experienced lower cancer incidence and enhanced treatment responses compared to those not on these medications.
Transformative Potential of GLP-1 Drugs
Dr. Judith Bray, vice-president of research at the Canadian Cancer Society, remarked on the transformative potential of these findings. She noted, “These rumbling or smoking guns have been firing off for well over a year now about this possibility. So, all of a sudden, the whole research world woke up.” The implications of this research could change how we perceive GLP-1 drugs, which have traditionally been associated with managing Type 2 diabetes rather than cancer prevention.
In a pivotal study presented at the ESMO Annals of Oncology, researchers analysed data from over 161,000 individuals, predominantly middle-aged and suffering from obesity but not diagnosed with diabetes or obesity-related cancers. Participants were divided into two groups: one received GLP-1 weight-loss injections, while the other engaged in standard dietary and exercise consultations. Remarkably, the results indicated that those on GLP-1 medications had a staggering 41 per cent lower risk of being diagnosed with an obesity-related cancer during the follow-up period.
Insights into Breast Cancer Prevention
Another notable study released on June 2 by JCO Oncology Practice explored the potential of GLP-1 drugs in breast cancer prevention. Conducted between January 2022 and June 2025, this research involved over 110,000 women aged between 45 and 80 who underwent breast imaging. Among these, nearly 14 per cent had been prescribed GLP-1 medications. The findings demonstrated that women using these drugs had a 35 per cent lower risk of developing breast cancer compared to those who did not. Further analysis matching over 15,000 women on GLP-1 drugs with those of similar backgrounds revealed a 31 per cent reduction in breast cancer odds for the drug users.
While Dr. Elizabeth McDonald, the lead researcher, acknowledged that this study was observational and does not conclusively establish causation, she affirmed that it contributes to the growing body of evidence suggesting GLP-1 medications warrant further investigation as potential cancer prevention tools.
The Need for Canadian Research
Breast cancer is projected to be the most commonly diagnosed cancer among women by 2026, accounting for an estimated 26 per cent of all cases, according to the Canadian Medical Association Journal. Kimberly Carson, CEO of Breast Cancer Canada, expressed optimism regarding the findings. She described the research as “very encouraging” and highlighted the potential for future developments in cancer prevention strategies. Carson stressed the necessity for more Canadian research in this field, stating, “I’d love to see some Canadian data on this. We have the capacity to run a study like this in Canada, and I think there’s an opportunity for Canada.”
Why it Matters
As Canada grapples with rising obesity rates—now affecting 68 per cent of adults aged 18 to 79, up from 60 per cent pre-pandemic—these findings signal a pivotal shift in how we approach healthcare, particularly in the realms of obesity management and cancer prevention. The potential of GLP-1 medications to mitigate cancer risks not only offers a novel avenue for patient care but also highlights the urgent need for further research in Canada. This could lead to transformative outcomes, not just for individuals managing chronic conditions but also for public health policy and preventive healthcare strategies going forward.
